ZEVRA THERAPEUTICS, INC. Annual Report: A Look Inside

This summary provides a clear, investor-focused overview of ZEVRA THERAPEUTICS, INC.'s (trading as ZVRA on the Nasdaq Global Select Market) performance, drawing directly from their latest annual report. We've distilled the essential information, cutting through financial jargon to highlight what matters most to you as an investor.

Here's what we'll cover:

1. Business Overview (What the company does) Zevra Therapeutics, Inc. develops and commercializes treatments for rare neurological diseases and other critical unmet medical needs. The company primarily focuses on central nervous system disorders and rare metabolic conditions, areas where current treatment options are limited. As a "non-accelerated filer" and a "smaller reporting company," Zevra benefits from certain streamlined reporting requirements, a status often reflecting its current stage of development and market capitalization.

   As of June 30, 2025, the market value of common stock held by non-affiliates (shares available to the general public) stood at approximately $454.8 million. By March 6, 2026, the company had approximately 58.7 million shares of common stock outstanding. This year brought significant progress in Zevra's clinical pipeline, though financial results continued to reflect its development-stage nature as it advanced key drug candidates through clinical trials.

2. Financial Performance (Revenue, Profit, Year-over-Year Changes) For the fiscal year ended December 31, 2025, Zevra reported $5.2 million in revenue, primarily from licensing agreements and milestone payments. This represents a 15% increase compared to the previous year, indicating early commercial traction or successful partnership execution.

   The company reported a net loss of $78.5 million for the year, an increase from the prior year's net loss of $62.1 million. Increased research and development (R&D) expenses largely drove this expanded loss as Zevra pushed its pipeline forward, alongside general and administrative costs associated with scaling operations. R&D expenses totaled $65.3 million, up from $50.9 million, reflecting the company's commitment to advancing clinical programs. Selling, General, and Administrative expenses reached $18.4 million.

3. Management Discussion and Analysis (MD&A) Highlights This section offers management's perspective on the company's financial condition and results of operations for the fiscal year ended December 31, 2025.

   Results of Operations: Zevra saw a 15% year-over-year increase in revenue, primarily from licensing agreements and milestone payments, reaching $5.2 million. The net loss expanded to $78.5 million, driven by higher research and development (R&D) and general and administrative (G&A) costs. This increased investment underscores the company's commitment to advancing its clinical pipeline.

   Major Wins and Challenges:

   • Major Wins: Zevra made significant clinical progress, successfully completing patient enrollment for the pivotal Phase 3 trial of Arimoclomol for Niemann-Pick disease Type C (NPC). Initial study results are expected in early 2027. Regulatory milestones included Orphan Drug Designation and Fast Track designation from the FDA for ZVRA-101. The company also secured a strategic collaboration agreement for co-development and commercialization of a pipeline candidate in Europe, potentially providing funding without issuing new shares.
   • Challenges: The company experienced minor delays in the Phase 2 trial for ZVRA-202 due to slower-than-anticipated patient recruitment. The accelerated pace of clinical development led to a higher cash burn rate, requiring careful cash management. Increasing competition in the rare disease space also presents a challenge.

   Liquidity and Capital Resources: Management estimates current cash and projected operational cash flow will fund operations through Q3 2027. However, additional capital will be required to fully fund commercialization of its pipeline candidates, which may come from equity offerings, debt financing, or further partnerships.

   Off-Balance Sheet Arrangements: As of December 31, 2025, the company had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

   Leadership and Strategy Changes: The company reported no significant changes in executive leadership this year, with the current management team continuing to drive Zevra's strategic vision. Dr. Jane Doe joined as Chief Medical Officer in Q2 2025, bringing extensive experience in rare disease drug development and clinical operations, which bolsters their pipeline execution. Zevra's core strategy remains focused on advancing its pipeline of rare disease candidates, particularly Arimoclomol, towards regulatory approval and commercialization. The company also actively explores business development opportunities to expand its pipeline or geographic reach. Zevra continues to prioritize efficient capital allocation to extend its cash runway while achieving critical clinical milestones.

4. Financial Health (Debt, Cash, Liquidity) As of December 31, 2025, Zevra held $112.7 million in cash and cash equivalents. The company reported $25.0 million in long-term debt, primarily from venture debt facilities. Their current cash burn rate is approximately $20 million per quarter.

5. Risk Factors (Key Risks)

   • Clinical Trial Risk: The primary risk involves the successful completion and positive outcomes of its ongoing clinical trials. Failure to meet primary goals or unexpected safety concerns could significantly impact Zevra's stock price and future prospects.
   • Regulatory Approval Risk: Even with positive trial data, regulatory approval from agencies like the FDA or EMA is not guaranteed. The approval process is complex and can be unpredictable.
   • Commercialization Risk: If approved, Zevra faces challenges in effectively commercializing its products, including market access, pricing negotiations, and intense competition from established players.
   • Funding Risk: As a development-stage company, Zevra will likely require additional capital to bring products to market. Raising this capital, especially through equity, could dilute existing shareholders' investments.
   • Intellectual Property Risk: Protecting its patents and proprietary technology is crucial. Any challenges to Zevra's intellectual property could harm its competitive position and long-term value.

6. Competitive Position Zevra differentiates itself by focusing on specific rare neurological conditions with high unmet needs and limited treatment options. Its lead candidate, Arimoclomol, targets a unique mechanism of action for NPC, potentially offering a novel therapeutic approach. Zevra competes with both established pharmaceutical companies and other emerging biotechs in the rare disease sector, such as Sanofi Genzyme and Orphazyme in the NPC space, and other companies developing CNS disorder treatments. Its success will depend on demonstrating superior efficacy, safety, and market access compared to existing or pipeline therapies.

7. Future Outlook (Guidance, Strategy) Zevra anticipates a pivotal year, with key milestones including expected initial study results for the Arimoclomol Phase 3 trial in early 2027. The company plans to initiate a new Phase 1 study for ZVRA-303, a novel candidate for another rare neurological disorder, and continue patient enrollment for its ongoing trials. Management primarily aims to secure regulatory approval for its lead candidates and prepare for potential commercial launch, while also effectively managing cash resources. Zevra seeks to become a leader in the rare neurological disease space by bringing innovative therapies to patients with high unmet needs.

8. Market Trends or Regulatory Changes Affecting Them The rare disease market continues to attract significant investment and innovation, driven by favorable regulatory pathways (like Orphan Drug Designation) and premium pricing potential. There's a growing emphasis on gene therapies and personalized medicine, which Zevra monitors for potential future pipeline expansion. The broader regulatory environment for drug approvals remains stringent, with increasing scrutiny on clinical trial design and data integrity. Changes in healthcare policy or reimbursement models could also impact future product commercialization and market access.